Posts tagged as:

PPH

The healthcare industry has been one of the fastest growing segments in the market, with the iShares Dow Jones U.S. Healthcare ETF (IYH, A) outperforming the SPDR S&P 500 ETF (SPY, A) over the past 1-year, 5-year, and 10-year periods. By enabling investors to purchase diversified exposure in a single security, exchange-traded funds represent a great way to efficiently and cost-effectively build healthcare exposure into a portfolio [see Select Sector SPDR ETFs Head-To-Head]. [click to continue…]

{ Comments on this entry are closed }

After yesterday’s pullback, investors welcomed several better-than-expected earnings reports, which helped outweigh sluggish economic data. Oil giant Valero (VLO) topped analysts expectations in their fourth quarter earnings report, posting profits that came in well above estimates. Pharma behemoth Pfizer (PFE) also reported solid earnings, with profits per share coming in at 47 cents. In economic news, the Conference Board’s consumer-confidence index came in lower-than-expected in January, while the S&P/Case-Shiller 20-city home price index rose for November. Despite today’s reports, investors still kept their focus on tomorrow’s Federal Reserve policy announcement [Be sure to check out the real estate news, trends, tips and tricks over at Dividend.com].

[click to continue…]

{ Comments on this entry are closed }

While some American’s were elated with Obama’s re-election, Wall Street made it quite clear who it had voted for as markets took a sharp nosedive in a post-election sell off immediately following the President’s victory. To many investors, Obama’s re-election has placed looming concerns over the Fiscal Cliff to the forefront, as the automatic round of […]

{ Comments on this entry are closed }

The past few weeks have seen a nice rally to start off the new year. With a number of encouraging earnings and data reports, stocks have been on a tear, with the S&P hitting 1,300 for the first time in several months. But last Friday’s GDP report, though representing strong growth, may have adverse effects […]

{ Comments on this entry are closed }

This time last year, investors were generally thrilled with the performances of their portfolios, which had continued to bounce back nicely from the devastating recession that hit in 2008. Unfortunately, few are feeling the same sense of accomplishment as 2011 draws to a close; this year has been frustrating in that a few large, swift […]

{ Comments on this entry are closed }

Van Eck has begun the process of converting six HOLDRS products offered by Merrill Lynch into traditional ETFs that will be included under the Market Vectors lineup, offering investors an opportunity to exchange their receipts in HOLDRS trusts for shares in the new ETFs. The exchange requires affirmative action on the part of investors, meaning […]

{ Comments on this entry are closed }

RBS rolled out its fifth ETN this week, debuting a product that offers exposure to the world’s largest pharmaceutical firms. The new Global Big Pharma ETN (DRGS) will seek to replicate the NYSE Arca Equal Weighted Pharmaceutical Total Return Index, a benchmark that consists of equal allocations to about 16 different companies involved in various […]

{ Comments on this entry are closed }

Pharmaceutical companies have long been popular investments as they offer relatively inelastic products as well as strong dividend yields that give both growth and value investors something to buy into. As far as the ETF world is concerned, there are four products that allow investors to gain access to this investment class. But with the […]

{ Comments on this entry are closed }

The competitive landscape of the ETF industry has evolved rapidly over the last several years, with several new players–both big and small–making a push into the space. From financial giants such as RBS and Citi to relative unknowns such as Javelin and Precidian, the roster of active ETF issuers has grown to nearly four dozen. […]

{ Comments on this entry are closed }

Van Eck announced last week a partnership with Merrill Lynch that may ultimately lead to the conversion of several HOLDRS products to soon-to-be-launched Market Vectors ETFs. As part of the agreement, Van Eck will introduce six new ETFs that maintain the same tickers as the existing HOLDRS but that will be part of the Market […]

{ Comments on this entry are closed }

The past few weeks have been focused on one of the biggest debt crises in U.S. history, as lawmakers sought to find a way through a $14.3 trillion pile of debt. While major equities have suffered their worst stretch in over a year, this quarter’s earnings season has taken a back seat to the debt […]

{ Comments on this entry are closed }

Equities Poised To Pop

by on August 1, 2011

Investors went along for a downhill  ride last week as debt woes plagued Wall Street, sending the S&P 500 lower by nearly 4% for the week. Corporate earnings were mostly surprises to the upside, but equities failed to stage a meaningful comeback since investors were more concerned with the debt ceiling drama at home. As […]

{ Comments on this entry are closed }